The Effect of Tranexamic Acid for Total Hip Arthroplasty

The Effects of High Doze Tranexamic Acid Application on Hemorrhage, Blood Transfusion, Fibrin Degradation Products, and Kidney Functions for Total Hip Arthroplasty

Status

UNKNOWN

Phases

Phase 4

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT02094066

Enrollment

Registered

2014-03-21

Start date

2014-03-31

Completion date

2014-07-31

Last updated

2014-03-26

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Hemorrhage

Keywords

tranexamic acid, total hip arthroplasty

Brief summary

The aim of this study is to investigate the effects of tranexamic acid on hemorrhage, blood transfusion, fibrin degradation products and kidney functions for total hip arthroplasty.

Detailed description

Orthopedic surgery may be associated with substantial blood loss requiring transfusion of erythrocytes.Transfusion of allogeneic erythrocytes is not free of adverse events and has been associated with transmission of infectious diseases, increased postoperative bacterial infection, immune sensitization, and transfusion related acute lung injury. Measures taken to allay concerns about the safety of blood transfusions have translated into the increasing cost of allogeneic blood units. Blood banks regularly undergo blood shortages. For these reasons, there is a need to reduce allogeneic blood transfusions. A number of effective interventions have been developed, such as preoperative autologous donation, cell salvage, or the use of erythropoietin. Pharmacologic agents such as aprotinin, tranexamic acid, or epsilon-aminocaproic acid (EACA) could reduce perioperative blood loss by interfering with fibrinolysis.

Interventions

DRUGtranexamic acid

preoperative ıv 50 mg/kg tranexamic acid infusion at 45 minutes

DRUGserum physiologic

preoperative 100 cc ıv serum physiologic

Study design

Allocation

RANDOMIZED

Intervention model

PARALLEL

Primary purpose

TREATMENT

Masking

QUADRUPLE (Subject, Caregiver, Investigator, Outcomes Assessor)

Eligibility

Sex/Gender

ALL

Age

18 Years to 75 Years

Healthy volunteers

Inclusion criteria

* ASA 2-3 * 18-75 age * total hip arthroplasty surgery * regional anesthesia

Exclusion criteria

* allergies to drug * liver and kidney failure * ischemic heart disease * coagulopathy

Design outcomes

Primary

Measure	Time frame	Description
hemorrhage	intraoperative	the amount of bleeding in aspirator and sponges

Secondary

Measure	Time frame
erythrocyte transfusion	intraoperative and postoperative 3 days

Countries

Turkey (Türkiye)

Contacts

Primary Contactseher orbay yasli, resident

sehersin81@hotmail.com+905052401933

Backup Contactzeynep tosun, prof

zeynep@erciyes.edu.tr+905326640648

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026